Precisio Biotix Therapeutics Receives Additional Funding to Advance a New Approach to Bacterial Vaginosis (BV), A Major Women’s Health Issue
DOVER, Del.--(BUSINESS WIRE)--Precisio Biotix Therapeutics, Inc. (“Precisio”), today announced new funding from Gates Foundation to advance a potential new treatment for bacterial vaginosis (BV), one of the most common vaginal conditions affecting women worldwide.BV occurs when beneficial bacteria that help maintain vaginal health are displaced by harmful bacteria. These harmful bacteria, particularly Gardnerella, can form protective biofilms that make them difficult to eliminate with antibiotic